Pricing
  1. JP-listed companies
  3. Financials
  4. Revenue growth (%)

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Dec 31, 2025-50.3-106.51%
Dec 31, 2024773.3-1635.81%
Dec 31, 2023-50.3-108.22%
Dec 31, 2022612.4-760.30%
Dec 31, 2021-92.7+187.66%
Dec 31, 2020-32.2-101.68%
Dec 31, 20191,922.9-2108.01%
Dec 31, 2018-95.8-112.16%
Dec 31, 2017787.2-2038.94%
Dec 31, 2016-40.6-194.22%
Dec 31, 201543.1-169.87%
Dec 31, 2014-61.7+181.60%
Dec 31, 2013-21.9-75.16%
Dec 31, 2012-88.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat